536 related articles for article (PubMed ID: 27034984)
21. Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.
Vanan MI; Underhill DA; Eisenstat DD
Neurotherapeutics; 2017 Apr; 14(2):274-283. PubMed ID: 28233220
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma.
Hashizume R
Neurol Med Chir (Tokyo); 2017 Jul; 57(7):331-342. PubMed ID: 28592748
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma.
Hashizume R; Andor N; Ihara Y; Lerner R; Gan H; Chen X; Fang D; Huang X; Tom MW; Ngo V; Solomon D; Mueller S; Paris PL; Zhang Z; Petritsch C; Gupta N; Waldman TA; James CD
Nat Med; 2014 Dec; 20(12):1394-6. PubMed ID: 25401693
[TBL] [Abstract][Full Text] [Related]
24. Pediatric low-grade gliomas: how modern biology reshapes the clinical field.
Bergthold G; Bandopadhayay P; Bi WL; Ramkissoon L; Stiles C; Segal RA; Beroukhim R; Ligon KL; Grill J; Kieran MW
Biochim Biophys Acta; 2014 Apr; 1845(2):294-307. PubMed ID: 24589977
[TBL] [Abstract][Full Text] [Related]
25. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
[TBL] [Abstract][Full Text] [Related]
26. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
[TBL] [Abstract][Full Text] [Related]
27. Pediatric low-grade glioma in the era of molecular diagnostics.
Ryall S; Tabori U; Hawkins C
Acta Neuropathol Commun; 2020 Mar; 8(1):30. PubMed ID: 32164789
[TBL] [Abstract][Full Text] [Related]
28. The growing role of epigenetics in childhood cancers.
Panditharatna E; Filbin MG
Curr Opin Pediatr; 2020 Feb; 32(1):67-75. PubMed ID: 31895160
[TBL] [Abstract][Full Text] [Related]
29. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
[TBL] [Abstract][Full Text] [Related]
30. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
Kasper LH; Baker SJ
Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
[TBL] [Abstract][Full Text] [Related]
31. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
Feng J; Hao S; Pan C; Wang Y; Wu Z; Zhang J; Yan H; Zhang L; Wan H
Hum Pathol; 2015 Nov; 46(11):1626-32. PubMed ID: 26297251
[TBL] [Abstract][Full Text] [Related]
32. H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas.
Gielen GH; Gessi M; Hammes J; Kramm CM; Waha A; Pietsch T
Am J Clin Pathol; 2013 Mar; 139(3):345-9. PubMed ID: 23429371
[TBL] [Abstract][Full Text] [Related]
33. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
[TBL] [Abstract][Full Text] [Related]
34. A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells.
Misuraca KL; Hu G; Barton KL; Chung A; Becher OJ
Neoplasia; 2016 Jan; 18(1):60-70. PubMed ID: 26806352
[TBL] [Abstract][Full Text] [Related]
35. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas.
Juratli TA; Qin N; Cahill DP; Filbin MG
Pharmacol Ther; 2018 Feb; 182():70-79. PubMed ID: 28830841
[TBL] [Abstract][Full Text] [Related]
37. Deregulated chromatin remodeling in the pathobiology of brain tumors.
Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
[TBL] [Abstract][Full Text] [Related]
38. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.
Jones C; Baker SJ
Nat Rev Cancer; 2014 Oct; 14(10):. PubMed ID: 25230881
[TBL] [Abstract][Full Text] [Related]
39. Investigational new drugs for brain cancer.
Staedtke V; Bai RY; Laterra J
Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
[TBL] [Abstract][Full Text] [Related]
40. Viability screen on pediatric low grade glioma cell lines unveils a novel anti-cancer drug of the steroid biosynthesis inhibitor family.
Ajeawung NF; Maltais R; Jones C; Poirier D; Kamnasaran D
Cancer Lett; 2013 Mar; 330(1):96-105. PubMed ID: 23201138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
